Medication info

Volulight Injection 6%

Prescription medicationIntravenous injection
Ingredient · strength
Hydroxyethyl starch (130/0.4)›6g / 100mLSodium Acetate Hydrate›463mg / 100mLSodium Chloride›602mg / 100mLPotassium Chloride›30mg / 100mLMagnesium Chloride Hydrate›30mg / 100mL
Manufacturer / importer
Fresenius Kabi Korea Ltd.
Appearance
Colorless to pale yellow injection solution in a colorless transparent intravenous bag
Packaging
500ml/bag x 20
Approval status
Active

MFDS item code 200908761 · Approved 2009.12.11 · Insurance code 650901710

Summary

Main use
Rapid isovolemic hemodilution when alternative treatment is unsuitable; treatment and prevention of reduced blood volume
Who receives it
Adults
Adult administration
1. Administer by intravenous infusion. Administer the initial 10~20mL slowly while carefully monitoring the patient (there is a possibility of an anaphylactoid reaction). 2. The daily dose and infusion rate are determined according to the patient's blood loss, maintenance or restoration of hemodynamic parameters, and hemodilution. Repeated administration over several days may be given depending on the patient's condition, and the duration of administration is determined according to the duration and extent of blood volume reduction, shock, hemodynamic effects, and hemodilution. However, the maximum daily dose is 50mL per kg of body weight. (Equivalent to 3.0g hydroxyethyl starch, 6.85 mmol sodium, 0.2 mmol potassium, 0.075 mmol magnesium, 5.5 mmol chloride, and 1.7 mmol acetate per kg of body weight)

Ingredients

Importer
Fresenius Kabi Korea Ltd.

Efficacy & effects

Rapid isovolemic hemodilution when alternative treatment is unsuitable; treatment and prevention of reduced blood volume

  • Blood volume reduction
View approved original text

This drug is used solely for the treatment and prevention of blood volume reduction when other alternative therapies are not appropriate. It is also used in rapid normovolemic hemodilution (ANH).

How it is given

Adult administration

1. Administer by intravenous infusion. Administer the initial 10~20mL slowly while carefully monitoring the patient (there is a possibility of an anaphylactoid reaction). 2. The daily dose and infusion rate are determined according to the patient's blood loss, maintenance or restoration of hemodynamic parameters, and hemodilution. Repeated administration over several days may be given depending on the patient's condition, and the duration of administration is determined according to the duration and extent of blood volume reduction, shock, hemodynamic effects, and hemodilution. However, the maximum daily dose is 50mL per kg of body weight. (Equivalent to 3.0g hydroxyethyl starch, 6.85 mmol sodium, 0.2 mmol potassium, 0.075 mmol magnesium, 5.5 mmol chloride, and 1.7 mmol acetate per kg of body weight)

Precautions

This drug may increase the risk of mortality, kidney damage, and excessive bleeding and should be used only when other treatment options are not appropriate. It should especially not be administered to patients with sepsis, renal impairment, or severe illness. When administered to patients with hypovolemia, careful evaluation of the risk of kidney damage and liver function decline should be conducted, and the use of crystalloids should be prioritized for patients at high risk. This drug should not be administered to patients with sepsis, severe liver disease, fluid overload, renal failure, severe heart failure, severe coagulopathy, those undergoing dialysis, patients with intracranial hemorrhage, severe electrolyte abnormalities, patients allergic to any component of this drug, and generally to severely ill patients. Caution should be exercised when administering this drug to patients with heart failure, a history of liver disease, severe dehydration, coagulopathies, or corn allergies, as dosage adjustments may be needed. During administration of this drug, rare hypersensitivity reactions, such as anaphylaxis, may occur, so patients should be monitored closely, and in case of adverse symptoms, administration should be stopped immediately and emergency treatment provided. Moreover, excessive administration may lead to coagulation function problems, and cardiovascular and metabolic abnormalities, such as atrial fibrillation or metabolic acidosis, may occur. In cases of overdose, circulatory overload, such as pulmonary edema, may occur, so caution is needed, and in such cases, administration should be stopped immediately, and diuretics or vasodilators should be used if necessary. It is very important to regularly check and monitor serum electrolyte levels, kidney function, and fluid balance during administration of this drug. During pregnancy, this drug should only be used when the benefits of treatment outweigh the risks to the fetus, and during breastfeeding, it is advised to carefully decide on administration as it is not known if this drug is secreted in breast milk. The safety and efficacy in pediatric patients have not been adequately established, so it is advisable to avoid use in pediatric patients. This drug should not be mixed with other medications, and the transparency and packaging of the product should be checked before use. During storage, keep out of reach of children, store in a sealed container, and keep in a cool place below 25 degrees; avoid freezing. This drug should only be used for intravenous injection, and any remaining drug after opening should be disposed of immediately.

Side effects

  • Anaphylactic reaction
  • influenza-like symptoms
  • bradycardia
  • tachycardia
  • bronchospasm
  • dyspnea
  • non-cardiogenic pulmonary edema
  • rash
  • pruritus
  • coagulation disorder
Show 9 more
  • decreased hematocrit
  • decreased plasma protein concentration
  • atrial fibrillation
  • metabolic acidosis
  • vomiting
  • chills
  • fever
  • headache
  • increased serum amylase concentration

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent air and moisture from entering, and it is best kept in a cool place below 25 degrees. By storing in this way, the drug's efficacy can be maintained for a longer period.

Appearance and packaging

Appearance

Colorless to pale yellow injection solution in a colorless transparent intravenous bag

Package unit

500ml/bag x 20

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.